InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, announced today that one of the company’s neurosurgeons, Amer Khalil, MD, has been selected as the winner of an MDH Research Award, a grant given by MDHonors, to further InVivo’s research on spinal cord injury.
Dr. Khalil was awarded a grant of $10,000 for his project titled “Spinal cord repair using biomaterial-based drug-releasing strategies for reducing scarring and promoting regeneration.” Dr. Khalil’s project is important not only for InVivo’s second SCI product but also for the third product in the company’s portfolio, a platform intended for the reduction of fibrosis which has been developed to reduce scarring in both reparative surgical and dermatological applications. Combining the need for minimizing scarring after reparative surgery and the fast growing market demand for minimizing scarring following plastic surgery procedures, InVivo believes that this technology will result in millions of treatments per day in the U.S., and the company intends to lead the space.
“Amer has contributed to our team for over a year now, and we’re proud to see his peer researchers acknowledge what we see every day at InVivo,” said InVivo CEO Frank Reynolds. “Neurosurgeons have many career path options, and Amer’s commitment to helping move the ball forward in neurotrauma research makes him the perfect recipient for the MDHonors Research Award. This award clearly underscores the importance of InVivo’s spinal cord injury projects, and highlights Amer’s vital contributions to our efforts. This grant takes Amer one step further in his career as a surgeon-scientist and we’re delighted his contributions to our team are being recognized.”